Abstract: Nitric oxide (NO) is produced by the endothelial NOS (eNOS) in the intima and by the neuronal NOS (nNOS) in the adventitia of cerebral vessels. By activating soluble guanylyl cyclase, NO increases the production of 3'-5'cGMP, which relaxes smooth muscle cells and dilates the arteries in response to shear stress, metabolic demands and changes of pCO 2 (chemoregulation). 3'-5'cGMP is then metabolized by phosphodiesterases (PDEs). Aneurysmal subarachnoid hemorrhage (SAH) interrupts this regulation of cerebral blood flow (CBF). Oxyhemoglobin, gradually released from the subarachnoid clot enveloping the conductive arteries, scavenges NO and destroys nNOS-containing neurons. This deprives the arteries of NO, leading to vasoconstriction which initiates delayed vasospasm. This arterial narrowing increases shear stress and stimulates eNOS, which under normal conditions would lead to increased production of NO and dilation of arteries. However, this does not occur because of transient eNOS dysfunction evoked by increased levels of an endogenous NOS inhibitor, asymmetric dimethylarginine (ADMA). Increased ADMA levels result from decreased elimination due to inhibition of the ADMA-hydrolyzing enzyme (DDAH 2) in arteries in spasm by hemoglobin metabolites, bilirubin-oxidized fragments (BOXes). This eNOS dysfunction sustains vasospasm until ADMA levels decrease and NO release from endothelial cells increases. This NO-based pathophysiological mechanism of vasospasm suggests that exogenous delivery of NO, modification of PDE activity, inhibition of the L-arginine-methylating enzyme (I PRMT 3) or stimulation of DDAH 2 may provide new therapies to prevent and treat vasospasm. This paper summarizes experimental and early clinical data that are consistent with the involvement of NO in delayed cerebral vasospasm after SAH and which suggests new therapeutic possibilities.
INTRODUCTION
About 10 per 100,000 people suffer subarachnoid hemorrhage (SAH) from a ruptured intracranial aneurysm. Four to nine days after SAH, severe narrowing of the cerebral arteries develops in 30-70% of patients, [1] [2] [3] [4] which results in delayed ischemic neurological deficits (DIND) in 25% of patients with vasospasm. Half of these individuals suffer severe permanent neurological dysfunction or death due to DIND [1] [2] [3] . Despite, that the first report of DIND after subarachnoid hemorrhage was published in the midnineteenth century [5] and the presence of cerebral vasospasm has been known for more than a half of century, [6] its pathophysiology remains unclear.
Over the years, hemoglobin has been accepted as a cause of vasospasm [7] [8] [9] [10] . Since the discovery that nitric oxide (NO), an endothelium-derived relaxing factor, [11] has 1000 times greater affinity for hemoglobin than oxygen, [12, 13] neurosurgeons and neuroscientists have been interested in its role in the development of cerebral vasospasm after SAH [3, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . NO regulation of blood flow, [34] [35] [36] [37] [38] disappearance of neuronal (nNOS) immunoreactivity from arteries in spasm [39] and endothelial nitric oxide synthase (eNOS) dysfunction in cerebral vessels after SAH, [40] in addition to the above-*Address correspondence to this author at the Surgical Neurology Branch, National Institutes of Health, 10 Center Drive, Room 5D37, Bethesda, MD 20892, USA; Tel: 001-(301)-594-8117; Fax: 001-(301)-402-0380; E-mail: rysiek@ninds.nih.gov mentioned NO affinity for the heme moiety ("sink effect"), [12, 13] all suggest that NO depletion underlies vasospasm. All these findings have introduced new possibilities for NObased therapy for vasospasm [14, 18, 20, 24, 25, 28, [41] [42] [43] [44] [45] [46] [47] [48] [49] .
NO-Based Pathomechanism(s) of Delayed Cerebral Vasospasm
There is little doubt that ferrous hemoglobins (oxyhemoglobin and deoxyhemoglobin) slowly released from erythrocytes, oxidized to methemoglobin and metabolized after aneurysmal bleeding are directly and indirectly responsible for development of cerebral vasospasm. The concentration of ferrous hemoglobins peaks in close proximity to the arteries in the subarachnoid space around day 7 after SAH [10, 50] . NO, also known as an Endothelium-Derived Relaxing Factor, [11] dilates vessels reacting with a heme moiety guanylyl cyclase (Fig. (1) ) [12] . Due to the high affinity of NO to the heme moiety, oxyhemoglobin avidly scavenges NO produced by the cerebral arteries [12, 13] . At the same time, the nNOSexpressing (nitroxic, neuronal NOS-containing) neurons disappear from the arterial adventitia [39] due to neurotoxic effects of oxyhemoglobin, [51] [52] [53] diminishing NO availability in the vessel and leading to the initial vasoconstriction. However, this initial narrowing of the artery should stimulate eNOS expression due to increased shear stress [54] [55] [56] [57] [58] [59] . Subsequently, the increased NO production should counteract the decreased NO availability and lead to vasodilation [59] . But the persistence of delayed cerebral vasospasm, lowered cGMP levels in the arterial wall [60] and decreased nitrites in the CSF [17, 25, 61] with preserved expression of eNOS [39] suggesting the existence of a mechanism for endothelial dysfunction that decreases NO production [40] . There are at least two mechanisms potentially responsible for eNOS dysfunction after SAH: 1) increased activity of PDE leading to enhanced elimination of 3',5' cGMP [27] or 2) endogenous inhibition of eNOS by asymmetric dimethylarginine (ADMA), [17] probably in response to the presence of oxidized degradation fragments of bilirubin (BOXes) [17, 62] . Recently, the presence of BOXes and ADMA and their association with the degree and the time course of vasospasm have been reported in patients with SAH [62, 63] (Jung et al., in preparation). In the last phase of vasospasm, oxidation and elimination of BOXes reduce ADMA levels, [17] resulting in increased NO production by eNOS and recovery of endothelial dilatory activity. Thus, decreased NO availability in the cerebral conductive arteries, responsible for the development of vasospasm is evoked by the initial elimination of NO (first hit) and nNOS (second hit) by oxyhemoglobin, followed by the inhibition of eNOS by ADMA in the perivascular space (third hit).
These observations suggest that an NO-based mechanism of delayed cerebral vasospasm is not only multifactorial and affects different structures of the arterial wall but is also longitudinal (i.e., dependent on time-related changes in hemoglobin released from the subarachnoid clot).
Vasospasm Prevention and Treatment Based on NO Mechanisms
Incomplete understanding of the etiology of vasospasm has hindered the development of new treatments [64, 65] .
Although the pathogenesis of vasospasm after SAH is probably multifactorial, imbalance between vasoconstricting (endothelin-1, endothelium-derived constricting factor) and vasodilating influences on vascular tone in response to the presence of blood in the subarachnoid space is almost certainly at play [7, 9, 10, 50] . The above-mentioned Fig. (1) . This schematic presents nitric oxide (NO) signal transduction pathways in the cerebral arteries under normal conditions and after subarachnoid hemorrhage. Nitric oxide (NO) is produced by endothelial NO synthase (eNOS) in the intima and by neuronal NOS (nNOS) in the adventitia of cerebral vessels by cleavage from L-arginine. By activating soluble guanylyl cyclase (sGC) via nitros(yl)ation of the heme moiety of the enzyme, NO increases production of 3', 5'cGMP, which relaxes smooth muscle cells and dilates the arteries in response to shear stress, metabolic demands and changes of pCO 2 . Excess of NO is oxidized to nitrite and then to nitrate. The latter may be reduced back to NO by deoxygenated hemoglobin. 3', 5'cGMP is then metabolized by phosphodiesterases (PDE) to GMP. Aneurysmal subarachnoid hemorrhage (SAH) interrupts this regulation of arterial tone. Oxyhemoglobin, gradually released from the subarachnoid clot enveloping the conductive arteries, scavenges NO ("sink effect"; first hit) and destroys nNOS-containing neurons (nNOS toxicity; second hit). This deprives the arteries of NO and initiates delayed vasospasm. However, the arterial narrowing increases shear stress and stimulates eNOS, which under normal conditions would lead to increased production of NO and dilation of arteries. This effect does not occur because of transient eNOS dysfunction evoked by increased levels of an endogenous NOS inhibitor, asymmetric dimethylarginine (ADMA; third hit). Increased ADMA levels result from decreased elimination due to the inhibition of the ADMA-hydrolyzing enzyme (DDAH 2) by hemoglobin metabolites, bilirubin-oxidized fragments in arteries in spasm. This eNOS dysfunction sustains vasospasm until ADMA levels decrease and NO release from endothelial cells increases. This NO-based pathophysiological mechanism of vasospasm suggests that exogenous delivery of NO, modification of PDE activity, inhibition of the L-arginine-methylating enzyme (I PRMT 3), or stimulation of DDAH 2 may provide new therapeutic approaches to prevent and treat vasospasm. mechanisms of initiation, sustenance and resolution of delayed cerebral vasospasm open the possibility of developing vasospasm-preventing treatments with NO replacement and sequential targeted therapies.
Neuronal NOS Protection
One initial treatment shortly after SAH (until day 3) was proposed many years ago [66, 67] and it has been recently re-examined [68] . It facilitates the removal of the clot and bloody CSF, thereby decreasing levels of neurotoxic oxyhemoglobin in the vicinity of conductive vessels. Recombinant tissue plazminogen activator (rt-PA) has also been used in an attempt to enhance the effect of CSF drainage [66] . The removal of blood and its degradation products from the vicinity of the cerebral arteries theoretically could prevent the death of noxinergic neurons in the adventitia of the arteries and block initial spasm of the arteries by decreasing the availability of oxyhemoglobin that will be metabolized to BOXes. However, it seems unlikely that all, or perhaps even most, the blood can be removed. Since in this phase of vasospasm, the goal is to block oxyhemoglobin neurotoxicity, chelation of the ferrous iron oxyhemoglobin by an intracellular Fe +2 iron chelator such as dipyridyl has been examined [69] . Eliminating ferrous hemoglobin by either (or both) of these methods may prevent neuronal apoptosis in the adventitia thereby protecting a basic mechanism of the neuronal vasodilatory response [70] . These approaches would also reduce oxidative stress in the vicinity of conductive arteries, which should decrease the local levels of vasoactive heme metabolites, especially BOXes [62] .
Systemic NO Delivery
During the initial phase of vasospasm, NO replacement may be a helpful adjunct by quenching oxyhemoglobin, [71] leading to its oxidation (methemoglobin) and/or nitrosylation/nitration (SNO-hemoglobin, Fe(II)HbNO) [72, 73] . This NO-based quenching effect on ferrous hemoglobins ("the reversed sink effect") may also enhance the effectiveness of iron chelation.
Although the underlying mechanism of their effects was imprecisely known, nitrates (nitroglycerin (NTG) and sodium nitroprusside (SNAP)) were used for many years [74] for their vasodilatory effects [19, 75, 76] which we now know resulted from the enzymatic release of NO [77] . Intravenous delivery of NTG/SNAP prevented cerebral vasospasm in animal models [43, 78, 79] . However, the utility of NTG/SNAP was limited in animals and patients by its hypotensive effect [19, 78] . Therefore, it was proposed that NTG/SNAP should be combined with hypertensive agents [80] , but this solution did not find further support because of non-discriminative dilation of the cerebral vasculature and the development of a "steal syndrome", [7, 79, 81] increased intracranial pressure (ICP), [78] and lower perfusion pressure [82] . Thus, this approach did not spark clinical interest because of the high risk of potential ischemic complications and unpredictable pharamacokinetics, as nitrates require an enzymatic step to release NO [82] [83] [84] [85] .
Recently, NTG delivery in small-doses via a transdermal patch was shown to prevent cerebral vasospasm in a rabbit model of SAH while avoiding undesirable hypotension [79] .
However, the effectiveness of the low dose NTG had not been examined in clinical settings. In another study, intravenous therapy for 2-3 weeks with SNAP resulted in cyanide toxicity [86] . Recently, a newly developed NO donor [87] that spontaneously releases NO and has an extremely short half-life (1.8 seconds) had been examined in primate. However, no effect on delayed cerebral vasospasm was observed before hypotension developed (Pluta et al., unpublished data).
Despite the positive results in experimental settings and in some preliminary pilot clinical studies, nitrates as NO donors have limited effectiveness because of their significant peripheral vasodilatory effects, which lead to decreased blood pressure and potential serious consequences of decrease of CBF or cyanide toxicity.
Regional NO Delivery
Partial isolation of the brain vasculature for regional drug delivery was initiated many decades ago with the introduction of cerebral arteriography by E. Moniz in 1935 [88] . Intracarotid delivery, when used with approprite drugs, provides a pharmacokinetic advantage of drug delivery to the brain when compared to intravenous delivery [89, 90] . Intraarterial delivery to the brain was used for vasospasm with intra-arterial papaverine [91] [92] [93] . The key to achieving a meaningful pharmacokinetic advantage is the selection of drugs with a rapid total body clearance (short T 1/2 in systemic circulation), which provides a great fraction of brain exposure during the first pass through the cerebral circulation. Thus, to avoid peripheral effect of NO donor administration, a direct intracarotid/intracarebral arterial infusion was used and nitrates were replaced by nonenzymatic NO donors [14, 24, 94] . These donors included: NO gas solution, [14] 3-morpholinosydnonimine (SIN-1), [95] S-nitroso-N-acetylpenicillamine (SNAP), [18] Snitrosoglutathione (GSNO) [96, 97] and NONOates [24, 94, 98] . Among all NO donors, certain NONOates have proved to be the most promising due to the release of NO with optimal pharmacokinetics (half-life in the range of a few seconds) [24, 41, 45, 94, [98] [99] [100] [101] . ProliNO with a T 1/2 = 1.8 sec was created to provide NO effects only on the cerebral vasculature [24, 94, 98] . However, due to the disadvantages of long-term intracarotid/intracerebral arterial drug administration, this treatment has not been used in clinical trials.
Local NO Delivery
Local delivery has been used to describe administration of a drug directly in the vicinity of the targeted area. Until recently, with regard to NO delivery, this has meant that NO gas, NO donors, or nitrates had to be delivered to the effected tissue, the lung (inhalation) or topically on the surface of the exposed tissue etc.
In the instance of aneurysmal SAH, local administration has been affected by delivering NO donors intrathecally or intraventricularly [31, 46, 78, 102, 103] . Administration to the CSF avoids the systemic effects of intravenous administration. However, drug distribution delivered intrathecally after SAH is poorly understood. It is difficult to accept that any compound delivered intrathecally and/or intraventricularly will penetrate the thick clot enveloping the conductive arteries in the subarachnoid space to reach the arterial wall and exert its effect. Moreover, intrathecal and/or intraventricular delivery of a strong vasodilator can cause vasodilation in the more accessible vessels (i.e., those not covered by clot) more than those affected by spasm (and covered by clot) resulting in a "steal" syndrome [7, 81] . None of these issues have been properly addressed either experimentally or clinically and both success [46, 78, 103] and failure to improve cerebral vasospasm have been reported in small series with NO donors administrated into the CSF [102] .
An approach to avoid the above-mentioned drawbacks of NO delivery into the CSF might be avoided by the delivery of an NO donor directly into vicinity of the most susceptible arteries by placing a controlled-release polymer loaded with the NO donor at the time the aneurysm is surgically repaired. This method was reported to prevent vasospasm with an NO donor in a primate model of SAH [104] . Obvious disadvantages of this method are that not all candidate vessels for vasospasm after SAH are exposed via any surgical exposure and it requires surgical access to the region of interest; with the rapidly increasing popularity of endovascular therapy [105] instead of surgical treatment for intracranial aneurysms, its potential use will be limited. Further, as described above the presence of clot in the vicinity may limit the distribution of vasoactive compounds.
Nitrite, the on Demand, Local but Systemically Administered NO Donor
There is another type of NO delivery, at least after SAH, which combines the convenience of systemic administration with the effectiveness of local drug delivery.
Intra-arterial and intravenous delivery of NO and NO donors increases nitrite and nitrosylated protein levels [106, 107] . This suggests that a portion of the delivered NO escapes scavenging by hemoglobin and reacts either with oxygen to form nitrite or with oxyhemoglobin to form nitrate or nitrosylated heme groups. In addition, NO nitrosates thiols and amines forming various species collectively are called NO-adducts, [107] [108] [109] [110] [111] constituting the so-called NO metabolome [112] . Any or all of the NO metabolome constituents may contribute to intravascular homeostasis and have NO-based effects on blood vessels [111] .
Intravenous infusion of nitrite has been shown to open the blood-tumor barrier similarly to an NO donor [94] and prevent the development of delayed cerebral vasospasm [25] . Also, nitrite dilates peripheral vessels, increasing regional blood flow, [108] protects the liver and heart against ischemia [113] and decreases pulmonary hypotension [114] . These findings suggest that nitrite is a reservoir for intravascular NO, which may release NO on demand, particularly during inhibition of NOS, low oxygen tension or exercise stress [72, 106, 113] . This effect is not necessarily limited to the blood and the vessels. Recently, nitrite, Snitroso-thiols and other NO-adducts including nitrosoamines have been found in other organs and tissues [115] suggesting that NO may also be released on demand from nitrite in the other tissues without the assistance of deoxyhemoglobin but with the contributions of other heme-containing proteins (P450, cytochrome c) and globins (myoglobin, neuroglobin, cytoglobin, GbX) [116] [117] [118] .
Nitrite has unique properties as an endogenous NO donor. Under physiological pH, nitrite forms nitrous acid, which can react with nitrite to form N 2 O 3 [106] . These reactive nitrogen species can nitrosate thiols (which can also be vasoactive) or, in the presence of an electron donor, produce NO [71, 106, 108] . Recently, this mechanism was confirmed both in vitro [119] and in vivo [25, 94, 108] showing that deoxyhemoglobin and presumably other deoxyheme proteins reduce nitrite to NO. These findings show that nitrite represents a major bioavailable pool of NO and presents a new physiological function for hemoglobin and other globins as nitrite reductases in vivo, potentially contributing to hypoxic vasodilation, oxygen sensing and other functions of NO.
NO, Nitrite, and Vasospasm
Decreased nitrite levels during cerebral vasospasm after SAH [17, 25, 61] are consistent with the hypothesis that decreased NO availability contributes to cerebral vasospasm. Reversal and prevention of cerebral vasospasm by NO/NO donors support this hypothesis [14, 24, 25, 31, 41, [45] [46] [47] 104] . In blood, nitrite is an endogenous NO donor [94, 106, 108] with deoxyhemoglobin acting as a nitrite reductase during hypoxic conditions [71, 108, 115, 119] . Similar conditions (i.e., presence of deoxyhemoglobin [50] and low pH [120] ) exist in microenvironments in the subarachnoid space after SAH. Thus, the lower CSF nitrite levels after SAH and during the development of vasospasm may be caused not only by decreased NO production by neuronal and endothelial NOS, but also by increased consumption of nitrite. Intravenous delivery of nitrite should overcome diminished NO production in the arterial wall after SAH.
We tested this hypothesis in a primate model of SAH [25] and demonstrated that continuous intravenous infusion of sodium nitrite for 14 days prevented the development of vasospasm. Concurrently, it increases nitrite levels in the blood and CSF and does so without decreasing blood pressure, and with clinically insignificant increases of blood methemoglobin levels.
Nitrite, is it Safe as an NO Donor?
For centuries, nitrite has been used in the meat, poultry and fish industries because of its antibacterial action, especially against botulinum spores, [121, 122] as well as for its reaction with myoglobin to produce an appealing pink color instead of significantly less desirable dark red-brown color [121, 123] . Despite its long history of use, nitrite received FDA attention in 1979 when a FDA-supported study reported that nitrite doubles the risk of lymphomas in rats [124] tumors, which have never been linked to nitrite or nitrosoamines in humans [122] . On the basis of this study, in 1978, the FDA and USDA recommended banning nitrite as a food additive [121] . Two years later, however, the results of the study were questioned and rejected by the FDA [122] .
Despite that nitrite may increase cancer incidence and tumor growth rate in animals, [125] there is only limited information on its effects in humans. Even though the FDA retreated from the issue, epidemiological studies assessing the health risk of nitrite continued, adding more confusion, because some of them confirmed the association between nitrite in food and development of neoplasms, especially in the brain [126] . Other studies were inconclusive [127] or completely rejected the association [128] . Furthermore, inhaled nitrite increased angiogenesis and accelerated growth of pre-existing tumors [129] and increased nitrite levels correlated positively with vasculo-and angiogenesis [130] . However, these effects have always been interpreted as a result of NO [130] [131] [132] [133] . No biological effect has been attributed to the presence of nitrite. In fact, the opposite effects have been reported, showing that NO inhibits angiogenesis and tumor growth [134] . All these results are even more difficult to interpret considering the recent ground-breaking study detailing the NO metabolome with the ubiquitous presence of nitrite and nitrosoamines in vivo [115] . These controversial and conflicting reports, [126] indicating the fact that nitrite is still used in the meat industry, [122] and the recently reported presence of nitrite and nitrosamines in many organs, including the brain, aorta, liver, kidney and heart [115] suggests that nitrite may not be as dangerous as suggested in the past and that carefully designed epidemiological studies of nitrite's biological role are necessary.
Other Therapies Addressing NO Depletion

Inhibition of ADMA Production
NO production is tightly controlled by multiple mechanisms requiring oxygen and L-arginine as substrates for enzymatic cleavage of NO by NOS (Fig. (1) ). For proper action, NOS requires the presence of several co-enzymes (heme, flavin adenine mono-and dinucleotides, NADPH, and tetrahydrobiopterin) as well as co-factors (calcium and calmodulin) [135, 136] . Furthermore, NOS activity is modulated by "internal" negative feedback between NO and a heme moiety of NOS [59] and by the competitive inhibition of NOS by ADMA, which is produced by double methylation of L-arginine by a type I protein-arginine methyl transferase (PRMT I) and degraded by dimethylarginine dimethylaminohydrolase (DDAH; Fig. (1) ) [137] .
In a primate model of SAH and in patients following a ruptured aneurysm, CSF levels of ADMA significantly increase and they do so concurrently with the development of vasospasm and gradually decrease with vasospasm resolution (Jung et al., in preparation) [17] . This suggests that endogenous inhibition of NOS by ADMA may be a source of endothelial dysfunction facilitating development of cerebral vasospasm following SAH, especially since DDAH2 activity disappears from arteries in spasm after SAH [17] .
Regulation of PRMT and DDAH activities has been studied recently. The second end-product of NOS activity, Lcitrulline, inhibits DDAH [137] and the S-nitrosylation of DDAH also inhibits its action [138] . Moreover, LDL cholesterol upregulates ADMA synthesis by the activation of PRMT, [139] suggesting that statins, drugs lowering plasma cholesterol levels, may at least indirectly affect DDAH activity. Statins correct endothelial dysfunction [140, 141] and increase eNOS activity and ameliorate vasospasm [142] [143] [144] [145] [146] [147] . Another cholesterol-lowering drug, probucol, promotes functional re-endothelization of stripped aorta [148] and preserves endothelial vasodilatory functions by reducing ADMA levels [149] . Probucol, has a high octanol/water partition coefficient (logP 10.91), [141] assuring significant penetration of the blood-brain barrier to inhibit increased ADMA levels in CSF after SAH and prevents the development of vasospasm in a primate model of SAH [150] . In in vitro experiments, probucol [149] potently decreased ADMA production by endothelial cells. In vitro it also increased nitrite levels, suggesting that it stimulated NO production [151] by eNOS [30, 152, 153] in response to increased DDAH activity [154] . These results encouraged a preclinical trial of probucol in a randomized, blinded, placebo-controlled experiment to investigate its effectiveness to inhibit increased ADMA levels in CSF after SAH and to prevent vasospasm. Unfortunately, probucol administered orally, despite achieving therapeutic serum levels, failed to inhibit ADMA increases in the CSF or prevent vasospasm after SAH [150] Despite the clear failure of probucol, the results of this study do not exclude the possibility that pharmacological inhibition of ADMA production [154] may prevent cerebral vasospasm. Estrogen [155] and all-trans-retinoic acid, which stimulate DDAH activity and increase NO production by eNOS, [154] deserve further examination as potential therapies in patients with SAH
Prevention of Vasospasm by PDE Selective Inhibitor
NO relaxes smooth muscle cells and dilates blood vessels stimulating soluble guanylyl cyclase (sGC), which produces 3'-5'cGMP. The latter sequestrates intracellular Ca 2+ , which relaxes vascular smooth muscle. Intracellular cGMP is inactivated by cyclic nucleotide phosphodiesterases (PDEs; Fig. (1) ). There are several isoforms of PDEs (Type 1-6); however, only PDE5 is abundant in vascular smooth muscle cells. PDE5 inhibitors (such as Viagra) have been used to increase blood flow and dilate blood vessels. However, their use is limited due to their non-selective activity. Recently, highly selective intracellular PDE5 inhibitors (E4021, SCH 51866) were introduced in clinical trials to control hypertension, pulmonary hypertension, respiratory distress, platelet aggregation and erectile dysfunction [156] [157] [158] [159] [160] [161] [162] [163] [164] . Increased 3', 5' cGMP in the cerebral arterial wall by selective inhibition of PDE5 may prevent development of delayed vasospasm after SAH [165, 166] . Well-designed studies need to be carried out to elucidate the role of cGMP and PDE inhibitors in delayed vasospasm.
SUMMARY
Despite significant progress in understanding the pathophysiology of delayed cerebral vasospasm following a ruptured intracranial aneurysm, there is no effective treatment for this dreadful complication of SAH. However, recent advances in understanding the roles of NO, NO donors, NOS, and nitrite in physiological and pathophysiological conditions suggest the possible development of therapies, which will address the decreased NO availability in cerebral arteries and successfully prevent or reverse cerebral vasospasm after SAH.
